Abbott Reports In-Line Q1 Results, Updates FY26 Guidance Post-Exact Sciences Acquisition

summarizeSummary

Abbott Laboratories reported first-quarter results aligned with expectations and updated its full-year guidance, incorporating the financial impact of the recently completed Exact Sciences acquisition.

check_boxKey Events

• First-Quarter 2026 Results Announced

  Abbott reported first-quarter GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15, reflecting 6 percent growth. Sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis, aligning with expectations.

• Full-Year 2026 Guidance Updated

  The company projects full-year 2026 comparable sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.38 to $5.58. This guidance includes a $0.20 per share dilution related to the Exact Sciences acquisition.

• Exact Sciences Acquisition Completed

  Abbott completed its acquisition of Exact Sciences on March 23, 2026, establishing a leadership position in the oncology diagnostics market and adding a new high-growth vertical to its portfolio.

• Positive Product Development Updates

  Abbott announced a collaboration for a next-generation EV-ICD system, positive early results for the Amulet 360™ Left Atrial Appendage Occluder, and clinically meaningful HbA1c reduction with FreeStyle Libre® in Type 2 diabetes patients.

auto_awesomeAnalysis

This filing provides Abbott's official first-quarter results, which were aligned with expectations. Crucially, it updates the full-year 2026 financial guidance to reflect the recently completed Exact Sciences acquisition, quantifying its dilutive impact while maintaining a positive outlook for accelerating growth. This clarity on future performance, combined with positive product development news, is important for investors, especially with the stock trading near its 52-week low, as it provides a baseline for future valuation.